Optinose Announces Proposed Public Offering of Common Stock
November 15, 2021 17:40 ET
|
Optinose, Inc.
YARDLEY, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
November 15, 2021 16:26 ET
|
Optinose, Inc.
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and...
Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
November 10, 2021 17:50 ET
|
Optinose, Inc.
Conference Call and Webcast to be held November 16, 2021 at 8:30 a.m. Eastern Time YARDLEY, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on...
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
October 28, 2021 06:59 ET
|
Optinose, Inc.
Company Expects Top-Line Results in Second Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose to Present at the Cantor Virtual Global Healthcare Conference
September 22, 2021 16:15 ET
|
Optinose, Inc.
YARDLEY, Pa., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 25, 2021 17:00 ET
|
Optinose, Inc.
YARDLEY, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today...
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
August 11, 2021 07:00 ET
|
Optinose, Inc.
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call...
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
July 30, 2021 08:00 ET
|
Optinose, Inc.
Company Expects Top-Line Results in First Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
July 28, 2021 08:00 ET
|
Optinose, Inc.
Preliminary XHANCE Net Revenue Growth of 79% Compared to Second Quarter 2020 Company reiterates XHANCE Net Revenue guidance for the Full Year of 2021 to be at least $80 million Conference Call and...
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
June 24, 2021 08:00 ET
|
Optinose, Inc.
YARDLEY, Pa., June 24, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...